<DOC>
	<DOCNO>NCT00097045</DOCNO>
	<brief_summary>This study design compare safety , tolerability antiviral effect omega interferon administer alone omega interferon administer ribavirin treatment subject chronic Hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Omega Interferon Alone Combination With Ribavirin Subjects With Hepatitis C</brief_title>
	<detailed_description>Omega interferon administer subcutaneously daily 48 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferon omega 1</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon Type I</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Male female Age 18 year 64 year Signed dated write informed consent form Infection HCV genotype 1 Two HCV RNA level great equal 100,000 International Units per mL ( IU/mL ) least seven day apart within 6 week prior randomization One alanine aminotransferase level great upper limit normal three month twelve month prior randomization At least one alanine aminotransferase level great upper limit normal three month twelve month prior randomization For duration treatment study drug subject duration treatment study drug plus additional six month subject take ribavirin , attenuation potential subject become pregnant , impregnate sexual partner , either : 1. use approve contraceptive method ( e.g. , IUD , oral contraceptive , doublebarrier method ) , 2. definitive exclusion surgery , radiation , menopause vasectomy For woman childbearing potential , negative serum Beta HCG pregnancy test within 14 day prior randomization Any additional plausible cause chronic liver disease , include active infection virus know suspected cause hepatitis Ascites current evidence portal hypertension ChildPugh classification B C liver disease Clinically apparent jaundice total bilirubin exceed 2 mg/dL ( Subjects Gilbert 's Syndrome meet inclusion exclusion criterion may admit study total bilirubin great 2 mg/dL ) Hemoglobin &lt; 12 g/dL A platelet count le 100,000 per mm3 A total white blood cell count le 3,000 per mm3 An absolute neutrophil count le 1,500 per mm3 Abnormal thyroid function ( Subjects require thyroid replacement stable , normal thyroid function may admit study ) History significant renal dysfunction History significant unstable cardiac disease Concurrent alcohol abuse illicit drug use Pregnant lactate woman Male partner woman pregnant Prior usage interferon Concurrent usage antiviral therapy , include another interferon , study Any concurrent infectious disease require antimicrobial treatment Positive test human immunodeficiency virus Positive test illicit drug A history malignancy ( except previously cure squamous cell basal cell carcinoma ) Known hypersensitivity interferon ribavirin relate compound A concurrent diagnosis depression stable least 60 day prior randomization Usage investigational drug within 30 day prior randomization ; plan usage investigational drug omega interferon course current study Prior randomization study Any condition , discretion investigator , would render individual inappropriate candidate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Omega Interferon</keyword>
	<keyword>Interferon</keyword>
	<keyword>HCV genotype 1</keyword>
</DOC>